The US giant will pay the money upfront for distribution rights for SSGJ-707 outside of China; the deal could be worth up to $4.8bn and Pfizer will also invest $100m into the HKEX listed firm.
Pfizer signs $1.25bn cancer antibody licensing deal with China's 3SBio
